| TCOYD - New and Noteworthy | | Print | |
| Monday, 13 December 2010 | |
For the week of December 13, 2010 - A Breakdown of All Things New in the
Diabetes World
Researchers Able to Isolate Stem Cells for Insulin Secreting Islet Cells Researchers at Georgetown University Medical Center announced Monday that they have made great strides in the search for a cure for type 1 diabetes. New findings suggest it may be possible for people with type 1 diabetes to grow their own insulin-producing cells from cells taken from men’s testicular tissue. Researchers were able to isolate stem cells, and turn them into insulin-secreting islet cells. These islet cells were then re-injected into mice with diabetes. The mice were then able to secrete insulin for up to one week. Click here to read TIME Magazine’s piece on this latest development: http://healthland.time.com/2010/12/13/using-sperm-producing-cells-to-treat-type-1-diabetes/ Medtronic Introduces New CareLink Pro 3 Software Medtronic, a long-time TCOYD sponsor, announced the FDA has approved the market launch of CareLink® Pro 3.0 Therapy Management Software. The software is unique in that it offers advanced decision support to healthcare professionals managing diabetes. The software analyzes data from a patient’s insulin pump, CGM device and glucose meter to identify the most important information regarding trends and observations. To read Medtronic, Inc.’s press release, click here: Merck Agrees To Buy Diabetes Treatment Developer SmartCells Merck & Co., also a TCOYD corporate sponsor, has acquired SmartCells, a privately held diabetes treatment developer. The new acquisition of SmartCells brings hope to research and development for a possible “smart” insulin regimen. This glucose responsive insulin will be able to better manage fluctuating blood glucose levels in people with diabetes. To read the news release, click here: http://www.merck.com/newsroom/news-release-archive/corporate/2010_1202.html Valeritas “V-Go” Pump Approved for People with Type 2 Diabetes As of December 8th, the FDA has approved Valeritas, Inc.’s new device for the treatment of diabetes. The “V-Go” pump is the first basal-bolus insulin pump device for the treatment of type 2 diabetes. The delivery device is disposable and features “h-patch” technology, designed for simplified delivery of insulin. To read more about this new device, click here: http://www.valeritas.com/pr/newsletter.shtml # # # |